The journal focuses on all types of endocrine diseases. These can be broadly categorized but not restricted to:
- Diabetes (type 1, type-2 diabetes. LADA).
- Obesity: (e.g. adipose tissue and metabolic homeostasis, brown adipose tissue and energy expenditure, leptin, endocrine control of energy balance).
- Metabolic syndrome and metabolic disorders (T2DM, Mixed dyslipidemia, Hypertension and increased cardiovascular risk – CAD, endocrine control of energy balance, endocrine-disrupting chemicals).
- Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH).
- Autoimmune endocrine disorders (Hashimoto’s thyroiditis, Graves’ disease, type 1 diabetes mellitus).
- Thyroid and parathyroid disorders (hyperthyroidism, hypothyroidism, hyperparathyroidism, osteitis fibrosa cystica).
- Adrenal disorders (Cushing’s syndrome, congenital adrenal hyperplasia, primary aldosteronism, Addison’s disease).
- Pituitary and bone diseases (e.g. Gigantism and Acromegaly, pituitary Cushing’s syndrome, Osteoporosis, osteogenesis imperfect, pituitary tumours, Dwarphism, congenital and acquired GH deficiency).
- Neuroendocrine diseases (diabetes insipidus, Kallman syndrome, neuroendocrine tumours).
- Endocrine tumours (thyroid cancer, pituitary tumours, pheochromocytoma, paraganglioma, ovarian cancer, ER/PR-positive breast cancer).
- Endocrine disorders of the reproduction system (e.g. hyperandrogenaemia, hirsutism, ovarian and metabolic dysfunction, menstrual cycle dysregulation, PCOs, endometriosis, male and female infertility, premature menopause).
- Endocrine disorders during pregnancy (e.g. diabetes mellitus, in-utero hyperglycaemia, thyroid function and miscarriage, stress hormones, endocrine disrupting chemicals -effects on mother, foetus and new-born).
- The microbiome of Endocrine Disorders
- Endocrinopathies Associated with Immune Checkpoint Inhibitor cancer treatment (Hypopituitarism, adrenocortical dysfunction, thyroid dysfunction and T1DM).
- Immunity and inflammation in endocrine diseases (e.g. COVID-19).
BMC Endocrine Disorders considers papers describing all well-established clinical and experimental approaches. However, we are particularly interested in studies describing state-of-the art experimental designs and new technologies, as well as studies of interdisciplinary nature. A non-exhaustive list of subjects is below:
- Tissue engineering, gene and cell therapy (e.g. stem-cell based therapy paracrine effects, direct cell-cell conversion/reprogramming, cell-cycle checkpoints release, 3D scaffolds, artificial organs, xenotransplantation).
- In vitro modelling of endocrine disorders (e.g. induced pluripotent stem cells-based, gene editing, animal models, organoids and organ-on-chip models).
- Immunotherapy of Endocrine Disorders
- System-based approaches in Endocrine Disorders (e.g. Network Biology, ‘Omics’, Systems Genetics).
- Surgical advancements
- Medical Imaging (e.g. computed tomography, magnetic resonance imaging, positron emission tomography, metabolic imaging, hyperpolarized 13C MRS/I).
- Computational modelling, artificial intelligence and endocrine disorders (e.g. medical devices, instrumentation, diagnosis and risk prediction, personalized treatment, medical imaging, biomarkers modelling, biomechanical modelling, biophysical modelling, drug effect modelling).
- Digital Technologies and Endocrine Disorders (e.g. medical sensors, mobile apps, remote medical care, patient follow-up, patient-related data, telemedicine, technology and assisted decision –making, robotic interventions, digital solutions in clinical workflows).
